Novartis on Monday became the latest Big Pharma player to jump into the molecular glue space. The Swiss drugmaker signed an exclusive development and commercialization agreement with Monte Rosa ...
We've rounded up the best cameras for photos and videos. Research ahead of Black Friday and use one this month to capture the Northern Lights or the Taurid meteor shower. The best cameras are a ...
Using one of the best photo storage and sharing sites is vital if you have lots of photos. Whether you’re a pro photographer, an avid enthusiast or just like taking lots of casual pictures ...
If approved, Kisqali could nearly double the number of patients eligible for CDK4/6 inhibitor adjuvant therapy,” said Patrick Horber M.D., President, International, Novartis. “Together with the recent ...
A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of ...
Novartis Pharmaceuticals Corp. was sued Thursday in federal court by four female pharmaceutical sales managers who say the company discriminated against them based on their age and gender when they ...
As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. In a court decision filed this ...
The Taliban has ordered media in three provinces of Afghanistan to stop airing images of any living being, a drastic step widely criticized by journalism and civil liberty groups. A Taliban ...
Novartis is spending $70 million upfront on a small molecule antitumor drug from the Chinese biotech Chengdu Baiyu.
Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small ...
Of the 2,100 entries from across the globe, 87 extraordinary photos were recognized for their originality, technique, and impact. They included the pink and purple hues of an electrical arc ...
Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback